Key Takeaways
- • CORE Biomedicine completed a $21 million Series A financing round co-led by UTokyo Innovation Platform and Elikon Venture, with participation from eight additional institutional investors including Mitsubishi UFJ Capital and CD Capital.
- • The company received a competitive grant from Japan's Agency for Medical Research and Development (AMED) under the Strengthening Program for Pharmaceutical Startup Ecosystem, supporting R&D activities and partnerships with Japanese universities, hospitals, and biopharmaceutical companies.
- • CORE Biomedicine operates a lineage-based precision oncology platform designed to identify and target core cancer drivers while expanding potential patient populations for novel therapies.
- • The company was founded with an oncology program portfolio licensed from Eisai, positioning it as a spin-out leveraging established pharmaceutical intellectual property in precision cancer therapeutics.
- • Capital and grant funding will advance CORE's lead programs through discovery and early clinical development stages, with Dr. Ping Zhu serving as Co-Founder and CEO.
Summary
CORE Biomedicine, a Boston-based biotechnology company, announced the completion of a $21 million Series A financing round focused on advancing lineage-based precision oncology therapeutics. The round was co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with additional participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. This diverse investor syndicate reflects strong institutional confidence in the company's oncology platform and development trajectory.
Beyond equity financing, CORE Biomedicine Japan, a wholly owned subsidiary, secured a competitive grant from the Japan Agency for Medical Research and Development (AMED) under its Strengthening Program for Pharmaceutical Startup Ecosystem. This grant provides dedicated funding for research and development activities while specifically supporting collaborations with Japanese universities, hospitals, and biopharmaceutical companies. The dual capital infusion—venture equity and AMED grant support—positions CORE to accelerate its development pipeline while establishing institutional partnerships across Japan's biopharma ecosystem.
CORE's core innovation centers on a lineage-based approach to precision oncology, designed to identify and target fundamental cancer drivers with precision while broadening the patient populations eligible for treatment. The company was founded with an oncology program portfolio licensed from Eisai, a major Japanese pharmaceutical company, establishing an intellectual property foundation for its therapeutic programs. According to Dr. Ping Zhu, Co-Founder and CEO, the financing and AMED support "represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines." These resources will fund advancement of lead programs through discovery and early clinical development phases, leveraging what management describes as the "rapidly evolving global biotech ecosystem" to develop innovative precision medicine therapeutics with potential market applications globally.
Beyond equity financing, CORE Biomedicine Japan, a wholly owned subsidiary, secured a competitive grant from the Japan Agency for Medical Research and Development (AMED) under its Strengthening Program for Pharmaceutical Startup Ecosystem. This grant provides dedicated funding for research and development activities while specifically supporting collaborations with Japanese universities, hospitals, and biopharmaceutical companies. The dual capital infusion—venture equity and AMED grant support—positions CORE to accelerate its development pipeline while establishing institutional partnerships across Japan's biopharma ecosystem.
CORE's core innovation centers on a lineage-based approach to precision oncology, designed to identify and target fundamental cancer drivers with precision while broadening the patient populations eligible for treatment. The company was founded with an oncology program portfolio licensed from Eisai, a major Japanese pharmaceutical company, establishing an intellectual property foundation for its therapeutic programs. According to Dr. Ping Zhu, Co-Founder and CEO, the financing and AMED support "represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines." These resources will fund advancement of lead programs through discovery and early clinical development phases, leveraging what management describes as the "rapidly evolving global biotech ecosystem" to develop innovative precision medicine therapeutics with potential market applications globally.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.